Ranolazine for the Treatment of Chest Pain in HCM Patients
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of RHYME is to evaluate the safety and efficacy of ranolazine in Hypertrophic
Cardiomypathy patients with chest pain or dyspnea despite treatment with standard medical
therapy. This is a small, pilot, open-label (non-randomized) study of an approved drug for
the treatment of angina in a novel patient population (adult patient population with
hypertrophic cardiomyopathy).